These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27133311)

  • 1. Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.
    Xu LX; Chen KY; Liu T; Zheng XT; Jiao ZQ; Xu Y; Li G
    Cardiovasc Ther; 2016 Aug; 34(4):225-33. PubMed ID: 27133311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention.
    Zheng XT; Chen KY; Liu T; Xu LX; Che JJ; Rha SW; Li GP
    Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):29-33. PubMed ID: 26414108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A
    J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Lee HJ; Yu CW; Hwang HK; Choi RK; Park JS; Li H; Ro YM
    Coron Artery Dis; 2013 Nov; 24(7):542-8. PubMed ID: 23994880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
    Song PS; Song YB; Yang JH; Hahn JY; Choi SH; Choi JH; Lee SH; Kim HS; Jang Y; Seung KB; Oh JH; Gwon HC
    Heart Vessels; 2015 Jul; 30(4):458-68. PubMed ID: 24682436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
    Youn YJ; Lee JW; Ahn SG; Lee SH; Choi H; Yu CW; Hong YJ; Kwon HM; Hong MK; Jang Y; Yoon J
    Am Heart J; 2014 Feb; 167(2):241-248.e1. PubMed ID: 24439986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
    Chen J; Meng H; Xu L; Liu J; Kong D; Chen P; Gong X; Bai J; Zou F; Yang Z; Li C; Eikelboom JW
    J Thromb Thrombolysis; 2015 Jan; 39(1):23-34. PubMed ID: 24869717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
    Verdoia M; Pergolini P; Barbieri L; Rolla R; Nardin M; Negro F; Suryapranata H; De Luca G;
    Thromb Res; 2018 Apr; 164():17-23. PubMed ID: 29475177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
    Yang TH; Jin HY; Choi KN; Do U; Kim HJ; Chung SR; Seo JS; Jang JS; Kim DK; Kim DS
    Int J Cardiol; 2013 Sep; 168(1):207-11. PubMed ID: 23106905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
    Noh Y; Lee J; Shin S; Lim HS; Bae SK; Oh E; Kim GJ; Kim JH; Lee S
    PLoS One; 2016; 11(3):e0150475. PubMed ID: 26939062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
    Lee SW; Park SW; Yun SC; Kim YH; Park DW; Kim WJ; Lee JY; Lee CW; Hong MK; Kim JJ; Park SJ
    Am Heart J; 2010 Feb; 159(2):284-291.e1. PubMed ID: 20152228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
    Choi YH; Suh SH; Choi JS; Kim CS; Sim DS; Bae EH; Lim SY; Ma SK; Jeong MH; Kim SW;
    Circ J; 2012; 76(10):2405-11. PubMed ID: 22785460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cilostazol in patients with acute coronary syndrome after percutaneous coronary intervention.
    Hu T; Ma H; Li H; Ren J
    Am J Ther; 2013; 20(2):151-3. PubMed ID: 22975664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Chen KY; Rha SW; Li YJ; Poddar KL; Jin Z; Minami Y; Wang L; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
    Circulation; 2009 Jun; 119(25):3207-14. PubMed ID: 19528339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Campo G; Tebaldi M; Vranckx P; Biscaglia S; Tumscitz C; Ferrari R; Valgimigli M
    J Am Coll Cardiol; 2014 Feb; 63(6):506-12. PubMed ID: 24161321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.